Azerbaijan vs Slovenia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Azerbaijan
52.0%
in 2025
Slovenia
55.0%
in 2025
Azerbaijan rank
153rd
Slovenia rank
150th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Azerbaijan
- Slovenia
How they compare
Slovenia currently reports 55.0% against 52.0% in Azerbaijan, a difference of 3.0%.
That makes Slovenia's figure about 1.1 times Azerbaijan's.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Slovenia ahead.
Azerbaijan ranks 153rd and Slovenia ranks 150th of 192 countries.
Across the 3 decades both report, Azerbaijan averaged higher in 1 and Slovenia in 1.
Head to head by decade
| Decade | Azerbaijan | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 42.0% | 28.0% | 14.0% | Azerbaijan |
| 2020s | 50.8% | 59.7% | 8.8% | Slovenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Azerbaijan or Slovenia?
- Slovenia, at 55.0% against 52.0% in Azerbaijan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Azerbaijan and Slovenia?
- 3.0%, with Slovenia ahead.
- How many years of comparable data are there for Azerbaijan and Slovenia?
- 18 years are reported by both, from 2008 to 2025.
- How do Azerbaijan and Slovenia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Azerbaijan ranks 153rd and Slovenia ranks 150th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.